Thank you

This live web event has ended. Thank you for attending.

Description

Unlock KRAS G12C for lung
cancer treatment decisions

Why should you register now for this webinar?
Hear a leading expert discuss the NCCN Guidelines^® and the importance of
KRAS G12C testing in NSCLC patients for a targeted therapy
Brought to you by: CAP TODAY
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenter: Anjen Chenn, MD, PhD

What will this webinar empower you to do?

• Understand KRAS G12C—a key emerging biomarker in non-small cell lung cancer (NSCLC)
• Learn about LUMAKRAS™—an approved treatment for NSCLC patients whose tumors harbor KRAS G12C mutations
  
• Review QIAGEN^® therascreen^® KRAS RGQ PCR Kit—an FDA-approved companion diagnostic to identify the KRAS G12C mutation
• Ask questions of our distinguished presenter